Cabopoint prospectively explores cabo in ICI refactory disease. RR of 30% post ipi/nivo and 25% post VEGF/ICI therapy show sequencing these agents is of benifit. It strengthens the data for Cabo in this setting which joins axi and pazo with prospect data in this setting. #GU23

Brilliant tour de force by Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) What lies in 2L and beyond in the treatment of #mRCC ? Amazing to see how far we have come and the prospects ahead! #GU23 OncoAlert

Out now! See the full publication on tailored immunotherapy in UC patients (TITAN TCC)!! authors.elsevier.com/c/1ggI05EIIgLp…

Excellent talk on penile cancer management by ⁦GAYA⁩, our visiting professor at ⁦Heinrich-Heine-Universität Düsseldorf⁩ !

A real pleasure and a great honour to spend 2 days # Dusseldorf University as invited professor by @ Prof. Peter Albers European Association of Urology (EAU) .A Great opportunity to perform a Robotic Radical Inguinal Lymphadenectomy for penile cancer and present our data from Fundació Puigvert Barcelona

The addition of Talazoparib(PARPi) to enza in CRPC has most effect in BRCA+ve tumors. Effects in the remaining HRR population are marginal or -ve (e.g. ATM). This is largely consistent with previous data for PARPi in CRPC, supporting the ODAC decision on olaparib #ASCO2023

🆕 Do not perform immediate cytoreductive nephrectomy in intermediate-risk patients who have an asymptomatic synchronous primary tumour and require systemic therapy. #RenalCellCarcinoma #EAUguidelines uroweb.org/guidelines/ren…

It’s published!

Online now: DARO safety data in comorbid patients! Efficacy and safety outcomes of darolutamide in patients with non-meta... sciencedirect.com/science/articl…

Great time with our visiting professor ⁦Juan Luis Vásquez⁩ !

Latest Publication by our Düsseldorf UroRad group sciencedirect.com/science/articl…

CheckMate 901 folks #ESMO23 Bladder Cancer Advocacy Network Mount Sinai Tisch Cancer Center Guru P. Sonpavde, MD Michiel van der Heijden Yüksel Ürün nejm.org/doi/full/10.10…

🔥Breaking News at #ESMO2023!🔥 EV302 is changing the game, unbelievable data (HR=0.45!!!) for metastatic urothelial cancer patients, really an evolution #EV302. Terrific presentation by Tom Powles. 🙌🔬🎗️ UroToday.com OncoAlert ESMO - Eur. Oncology

#Goosebumps #EV302 #ESMO23 Took 3 decades but a new SOC in 1L bladder cancer !!!!!! ⁦Tom Powles⁩ EV+Pembro irrespective…..WOW! 🤩

EV-302/Keynote-A39 game changer in mBCa OS 31.5 mo vs 16.1 👏🏼 Standing ovations for Tom Powles OncoAlert ESMO - Eur. Oncology silke gillessen

Insightful case discussion with an outstanding panel at #emuc23 with ⁦Axel S. Merseburger⁩ ⁦Yüksel Ürün⁩ , Kerstin Junker, N.Sanmamed and H. Thoeny!

No matter how you splice it , analyze it or criticize it .. this is hope .. something we have not been able to say in a very very long time for many of our #bladdercancer patients and I am here for it

Online now! Enfortumab Vedotin and Pembrolizumab — A New Perspective on Urothelial Cancer | NEJM nejm.org/doi/full/10.10…

JUST IN: U.S. FDA alert: FDA approves nivolumab in combination with cisplatin and gemcitabine for unresectable or metastatic urothelial carcinoma! Via ASCO U.S. FDA alert ! Trial presented ESMO - Eur. Oncology #ESMO23 and published NEJM OncoAlert brando Guru P. Sonpavde, MD Michiel van der Heijden

Congrats to Andreas and Yue for the best paper award! #eau24 sciencedirect.com/science/articl…